PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer.
Azad A, Arshad M, Generali D, Feldinger K, Gijsen M, Strina C, Cappelletti M, Andreis D, Leek R, Haider S, Kellokumpu-Lehtinen PL, Roxanis I, Harris AL, Shaaban AM, Joensuu H, Kong A.
Azad A, et al. Among authors: arshad m.
Cancer Commun (Lond). 2024 Nov 24. doi: 10.1002/cac2.12632. Online ahead of print.
Cancer Commun (Lond). 2024.
PMID: 39582148
No abstract available.